XERS

XERIS BIOPHARMA HOLDINGS INC

XERS·98422E103·US·Common Stock·Healthcare - Biotechnology-13D/G

XERS (XERIS BIOPHARMA HOLDINGS INC) is held by 126 institutional investors as of Q2 2026. Largest holders: BlackRock, Inc. ($115M), D. E. Shaw & Co., Inc. ($61.8M), VANGUARD CAPITAL MANAGEMENT LLC ($58.1M). Net institutional sentiment: Mixed.

126
Holders
(9 Elite)
$694.9M
Total Value
64% (130)
Consensus
83 buying - 47 selling
13F: Insider & Congress: Updated regularly
XERS

Smart Money Verdict

View all
Loading verdict
Held by 126 funds
9 elite

Who's Trading

Source dates: Price Aug 31, 2026 · Insiders Aug 21, 2026 · Activists Jul 31, 2026 · Congress none

InsiderPSPieper StevenSell $43KAug 12, 2026
InsiderMKMcCulloch KevinTax 22K shAug 1, 2026
InsiderSJShannon John Patrick JrTax 37K shAug 1, 2026
Checking access…

Top Holders

Checking access…
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
Increased
14.5M(+12.2%)$115M0.0%+96.56%
34
Increased
7.8M(+0.2%)$61.8M0.0%+40.36%
29
Increased
7.3M(+5.2%)$58.1M0.0%+40.47%
31
Increased
4.8M(+3.5%)$38.2M0.0%+137.81%
30
Increased
4.7M(+10.0%)$37.4M0.0%+140.60%
32
Increased
4.4M(+50.4%)$34.7M0.0%+31.93%
40
Decreased
2.9M(-29.7%)$22.9M0.0%+60.17%
0
Decreased
2.6M(-1.5%)$20.8M0.0%+42.76%
0
Increased
2.4M(+8.9%)$18.7M0.0%+28.15%
31
Decreased
2.3M(-9.2%)$18.5M0.0%+136.15%
0
Increased
2M(+5.5%)$15.9M0.0%+55.31%
30
Decreased
1.9M(-2.0%)$14.9M0.0%+39.17%
0
Increased
1.6M(+10.6%)$12.7M0.0%+176.20%
31
Decreased
1.6M(-1.2%)$12.6M0.0%+94.01%
0
Increased
1.5M(+10.5%)$12.2M0.0%+102.37%
31
Increased
1.5M(+9.8%)$11.8M0.0%+39.07%
31
Increased
1.4M(+67.4%)$11.4M0.0%+26.16%
41
Increased
1.4M(+59.8%)$11.1M0.0%+45.21%
40
Decreased
1.3M(-21.0%)$10.3M0.0%+30.55%
0
Increased
1.2M(+8.0%)$9.7M0.0%+39.33%
30

Showing 1-20 of 139

1 / 7
XERSXERSXERIS BIOPHARMA HOLDINGS INC

Other Healthcare stocks held by institutions

Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used